JH 009
Alternative Names: JH-009Latest Information Update: 22 Jan 2024
At a glance
- Originator Bivision Pharmaceuticals
- Class Antibody diagnostics; Imaging agents
- Mechanism of Action Diagnostic imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 12 Dec 2023 Preclinical trials in Solid tumours (Diagnosis) in China (Parenteral) before December 2023 (Bivision Pharmaceuticals pipeline; December 2023)